Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) announced that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. and Chief Financial Officer Andrew Saik will present in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The presentation is scheduled for Thursday, December 4, 2025 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s Events and Presentations web page.
Positive
- None.
Negative
- None.
News Market Reaction – ARVN
In the Nov 26 session, ARVN gained 2.48%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Investor conference | Neutral | +2.5% | Management scheduled a Piper Sandler fireside chat with webcast access. |
| Nov 24 | Clinical data preview | Positive | +2.2% | Multiple vepdegestrant abstracts accepted for presentation at SABCS 2025. |
| Nov 05 | Earnings and pipeline | Positive | +0.3% | Q3 2025 results with pipeline progress and NDA acceptance for vepdegestrant. |
| Nov 03 | Preclinical conference | Positive | -1.9% | Preclinical ARV-393 data to be presented at the ASH 2025 meeting. |
| Nov 03 | Investor conferences | Neutral | -4.1% | Participation in Guggenheim and Jefferies healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ARVN news has often seen modest positive reactions to clinical and earnings updates, while some conference-related announcements have coincided with negative or muted moves, indicating selective investor focus on data-rich catalysts.
Over the last few months, Arvinas highlighted several milestones. A Q3 2025 update on Nov 5 detailed financials, pipeline progress, and an NDA acceptance for vepdegestrant with a June 5, 2026 PDUFA date. Multiple conference and clinical-data announcements followed in November, including SABCS abstracts and ASH preclinical data. Today’s Piper Sandler appearance continues a pattern of active investor and scientific engagement rather than introducing new clinical or financial data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4 at 11:00 a.m. ET in New York.
A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
